Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present La Jolla Pharmaceutical Co. (NASDAQ: LJPC).

Full DD Report for LJPC

You must become a subscriber to view this report.


Recent News from (NASDAQ: LJPC)

La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology Association
SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced th...
Source: GlobeNewswire
Date: May, 17 2018 13:00
La Jolla's Financial Deal Is A Major Boost To Get The Ball Rolling
La Jolla Pharmaceutical ( LJPC ) recently announced that it had entered into a financing deal that would help it with the launch of its drug Giapreza. This not only helps the biotech with the commercial launch of the drug, but it also provides cash to fund other products in the pipeline ...
Source: SeekingAlpha
Date: May, 14 2018 02:27
Complimentary Stock Performance Review on La Jolla Pharma and Three Additional Biotech Industry Stocks
Stock Research Monitor: IMDZ, IMUC, and LXRX LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on LJPC sign up now at www.wallstequities.com/registration . On Thursday, the NASDAQ Composite ended the day at 7,404.97, up 0.89%; the Dow Jones Industrial Averag...
Source: ACCESSWIRE IA
Date: May, 11 2018 07:05
La Jolla Pharmaceutical misses by $0.74
La Jolla Pharmaceutical (NASDAQ: LJPC ): Q1 EPS of -$2.22 misses by $0.74 . Revenue of $0.8M. Cash and equivalents of $90.9M. Press Release More news on: La Jolla Pharmaceutical Co., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 10 2018 17:20
La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today a...
Source: GlobeNewswire
Date: May, 10 2018 16:46
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced ...
Source: GlobeNewswire
Date: May, 10 2018 16:45
CalciMedica Names Two Senior Executives to its Board of Directors
LA JOLLA, Calif. , May 1, 2018 /PRNewswire/ -- CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla , MD, currently Chief Medical Officer of La Jolla Pharmaceuticals Company (NASDAQ: LJPC), and Christopher Krueger , JD, MBA, a co-fou...
Source: PR Newswire
Date: May, 01 2018 17:15
Institutional Top Ideas Series: Broadfin Capital
In the last entry of this recently rebooted series, we took a look at top ideas from Deerfield Management (whose performance almost doubled that of the IBB during time frame we looked at). Keep in mind articles older than 10 days can only be accessed if you have a membership to ROTY or S...
Source: SeekingAlpha
Date: April, 05 2018 12:11
Rigel Pharmaceuticals To Test The FDA
Rigel Pharmaceuticals ( RIGL ) is about to find out just how soft the current FDA is with regards to less than perfect New Drug Application (NDA) submissions. When I last wrote about RIGL the company had generated data from two phase three studies of its drug fostamatinib in chronic/persis...
Source: SeekingAlpha
Date: April, 05 2018 03:06
U.S. Biotech/Pharma Sector Daily Observations Letter: March 26, 2018
The U.S. equity indexes rebounded today from key 200-day moving average support level after trade negotiations between the U.S. and China were reported. The buying accelerated later in the day indicating institutional interest (advancers: decliners= 68%: 23%). While it is unclear if we have se...
Source: SeekingAlpha
Date: March, 27 2018 05:49

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1833.1733.1633.5332.71270,520
2018-05-1733.1733.1633.5332.71270,320
2017-02-0319.6519.4919.759919.108153,387
2017-02-0219.4319.4319.6418.94148,029
2017-02-0119.5419.4419.9519.19141,913

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17124,456161,10077.2539Short
2018-08-16142,814188,05275.9439Short
2018-08-15111,093139,48779.6440Short
2018-08-14159,341212,96374.8210Short
2018-08-131,161,8031,991,73358.3313Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LJPC.


About La Jolla Pharmaceutical Co. (NASDAQ: LJPC)

Logo for La Jolla Pharmaceutical Co. (NASDAQ: LJPC)

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the development of therapies to treat human diseases that comprise cancer and chronic organ failure. Its lead product includes GCS , a clinical stage inhibitor designed to sequester and eliminate circulating levels of galectin for treating cancer with renal insufficiency and preventing chemotherapy toxicity, as well as for renal transplantation and cancer immunotherapy. The company is also developing LJPC , a subcutaneous formulation of GCS for renal transplantation and end stage renal disease LJPC , a synthetic galectin antagonist for heart failure and hepatic fibrosis and LJPC , a biological galectin antagonists for solid tumors. La Jolla Pharmaceutical Company was founded in and is headquartered in San Diego, California.

 

Contact Information

 

 

Current Management

  • George F. Tidmarsh / President, CEO
  • Chester Zygmont / CFO
  • George F. Tidmarsh /
  • Saiid Zarrabian /

Current Share Structure

  • Market Cap: $632,238,262 - 03/21/2018
  • Issue and Outstanding: 22,168,242 - 02/16/2018

 


Recent Filings from (NASDAQ: LJPC)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 06 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 27 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 27 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 20 2018

 

 


Daily Technical Chart for (NASDAQ: LJPC)

Daily Technical Chart for (NASDAQ: LJPC)


Stay tuned for daily updates and more on (NASDAQ: LJPC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: LJPC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LJPC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of LJPC and does not buy, sell, or trade any shares of LJPC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/